Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
7
×
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
7
×
seattle blog main
seattle top stories
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
bristol-myers squibb
cancer immunotherapy
investing
merck
nonalcoholic steatohepatitis
startups
abbvie
deals
drugs
eli lilly
What
drug
7
×
roundup
bio
cancer
fda
new
annual
approved
attention
biotech
companies
market
medicine
nash
news
patients
advantages
ahead
alzheimer’s
ambien
american
approval
asco
assessed
attendees
bar
biogen’s
biopharmaceutical
brings
camp’s
cash
chicago
city
clinical
combinations
communities
community’s
conference
convo
days
Language
unset
Current search:
cancer
×
drug
×
" seattle top stories "
×
" san francisco top stories "
×
" clinical trials "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More